Cancer therapy with a parvovirus combined with an HDAC inhibitor
AssigneeDeutsches Krebsforschungszentrum
InventorsAntonio Marchini, Jean Rommelaere, Nazim El-Andaloussi, Georgi Hristov, Junwei Li
Life of this patent
Estimating the term…
Abstract
Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.
Claims3
A method of treating cervical carcinoma or pancreatic carcinoma comprising the administration of an effective dose of a pharmaceutical composition containing (a) a H-1 parvovirus (H-1PV) and (b) a histone deacetylase inhibitor (HDACI) selected from the group consisting of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), wherein said effective dose comprises an amount sufficient to lead to the reduction or remission of said cervical carcinoma or pancreatic carcinoma, wherein (a) the H-1 parvovirus (H-1PV) and (b) the HDACI are sequentially administered.
Dependencies are inferred from the claim text.